#1 Clinical Trials Search in Europe

Myoviridae Bacteriophage Against Pseudomonas Aeruginosa (65.855 Bp)

This article discusses a clinical trial investigating the use of TP-122A, a bacteriophage cocktail, for treating ventilator-associated pneumonia (VAP). The study aims to assess the safety and tolerability of TP-122A when administered alongside standard of care treatment in adult patients with VAP. This Phase 1/2a trial is designed to evaluate multiple doses of TP-122A and its potential effectiveness in improving patient outcomes.

Table of Contents

What is MYOVIRIDAE Bacteriophage?

MYOVIRIDAE Bacteriophage against Pseudomonas aeruginosa (65.855 BP) is a type of virus that specifically targets and destroys the bacteria Pseudomonas aeruginosa. This bacteriophage, also known by its synonym Psa_F27/12, is part of a larger treatment called TP-122[1]. TP-122 is a cocktail of different bacteriophages designed to combat various harmful bacteria that can cause serious infections in hospitalized patients.

Target Condition: Ventilator-Associated Pneumonia

The primary focus of this treatment is Ventilator-Associated Pneumonia (VAP). VAP is a serious lung infection that can occur in patients who are on mechanical ventilation in hospitals[1]. It’s particularly dangerous because patients on ventilators are often already in critical condition, and this additional infection can be life-threatening.

Clinical Trial Overview

A clinical trial is currently underway to assess the safety and effectiveness of TP-122, which includes the MYOVIRIDAE Bacteriophage against Pseudomonas aeruginosa. This trial is a Phase 1/2a study, which means it’s one of the earliest stages of testing in humans[1]. The main goals of this study are:

  1. To evaluate how safe the treatment is when given to patients
  2. To see how well patients tolerate the treatment
  3. To determine if the treatment helps improve the condition of patients with VAP

How the Treatment Works

The treatment is given through nebulization, which means it’s turned into a fine mist that patients can inhale. Patients receive multiple doses every 8 hours for 7 days, in addition to the standard care they’re already receiving for their condition[1]. The bacteriophages in TP-122 are designed to target and destroy specific harmful bacteria without harming human cells or beneficial bacteria.

Who Can Participate in the Study?

The study has specific criteria for who can participate. Some key points include:

  • Patients must be 18 years or older
  • They must have VAP with a confirmed Pseudomonas aeruginosa infection
  • Patients need to be on mechanical ventilation but with stable ventilatory requirements
  • They should not have certain other medical conditions that could complicate the study

It’s important to note that there are many other specific inclusion and exclusion criteria that healthcare providers will use to determine if a patient is eligible for the study[1].

Safety Monitoring and Evaluation

Throughout the study, researchers will closely monitor patients for any side effects or adverse reactions. They will be looking at several factors, including:

  • Any adverse events that occur during treatment
  • Changes in laboratory test results
  • Changes in vital signs
  • Changes in electrocardiogram (ECG) readings

This careful monitoring helps ensure patient safety and provides valuable information about how the treatment affects the body[1].

Potential Benefits of the Treatment

While it’s too early to know for certain, researchers hope that this treatment could provide several benefits for patients with VAP, including:

  • Faster recovery from the infection
  • Reduced time on mechanical ventilation
  • Shorter stays in the intensive care unit (ICU)
  • Improved survival rates

However, it’s important to remember that these potential benefits are still being studied and are not guaranteed[1].

Aspect Details
Study Type Randomized, Parallel, Open-Label, Phase 1/2a
Intervention TP-122A (bacteriophage cocktail) + Standard of Care
Condition Ventilator-Associated Pneumonia
Primary Objective Evaluate safety and tolerability of TP-122A
Administration Nebulization every 8 hours for 7 days
Key Eligibility Adults (18+) with VAP and P. aeruginosa infection
Primary Endpoints Adverse events, lab parameters, vital signs, ECG changes
Secondary Endpoints Clinical cure, microbiological response, MV duration, ICU stay, survival

FAQ

  • What is TP-122A? TP-122A is a component of TP-122, a bacteriophage cocktail designed to target Pseudomonas aeruginosa infections in patients with ventilator-associated pneumonia. It contains specific bacteriophages that attack and kill the bacteria causing the infection.
  • What is the main objective of this clinical trial? The primary objective of this study is to evaluate the safety and tolerability of multiple doses of TP-122A when administered by nebulization every 8 hours for 7 days, in addition to standard of care treatment, in adult subjects with ventilator-associated pneumonia.
  • Who is eligible to participate in this trial? Eligible participants include adults aged 18 or older with ventilator-associated pneumonia, stable ventilatory requirements, and a confirmed Pseudomonas aeruginosa infection in the lower respiratory tract. Participants must also meet specific clinical criteria and be able to provide informed consent.
  • How is TP-122A administered in this trial? TP-122A is administered through nebulization, which means it is inhaled as a mist directly into the lungs. The treatment is given every 8 hours for 7 days, in addition to standard of care treatment for ventilator-associated pneumonia.
  • What are the main outcomes being measured in this trial? The main outcomes include the incidence of adverse events, changes in clinical laboratory parameters, vital signs, and electrocardiogram readings. Secondary outcomes include the proportion of patients achieving clinical cure, time to clinical cure, microbiological response, duration of mechanical ventilation, length of ICU stay, and survival rates.

Ongoing Clinical Trials on Myoviridae Bacteriophage Against Pseudomonas Aeruginosa (65.855 Bp)

  • Safety and tolerability study of bacteriophage cocktail TP-122A given by inhalation in adults with ventilator-associated pneumonia

    Not yet recruiting

    2 1 1
    Investigated drugs:
    The Netherlands Portugal

  • Study on the Safety and Tolerability of TP-122 for Treating Ventilator-Associated Pneumonia in Adults

    Not yet recruiting

    2 1 1
    Investigated drugs:
    France

Glossary

  • Ventilator-Associated Pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Bacteriophage: A virus that infects and replicates within bacteria. In this context, bacteriophages are used as a treatment to target specific bacterial infections.
  • Nebulization: The process of converting a liquid into a fine spray or mist, often used to administer medications directly to the lungs.
  • Standard of Care (SoC): The typical treatment or care given to patients with a specific condition, based on current medical knowledge and practices.
  • Clinical Cure: The resolution or significant improvement of signs and symptoms related to the infection, indicating successful treatment.
  • Microbiological Response: The effect of treatment on the presence of bacteria causing the infection, measured by laboratory tests.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.
  • Electrocardiogram (ECG): A test that measures the electrical activity of the heart to check for various heart conditions.
  • Mechanical Ventilation (MV): The use of a machine to help a patient breathe when they are unable to breathe sufficiently on their own.
  • Intensive Care Unit (ICU): A specialized hospital unit that provides intensive care and monitoring for critically ill patients.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-tp-122-for-treating-ventilator-associated-pneumonia-in-adults/